



9TH ANNUAL SUMMIT ON Life Sciences IP Due Diligence

*Where Life Sciences Industry Leaders Come Together to Tackle the Latest Challenges
in Assessing, Valuing, and Commercializing IP Assets*

February 9–10, 2027 | New York City Bar, New York, NY

2026 CONFERENCE CO-CHAIRS



Thomas L. Irving
Senior Partner
**The Marbury Law
Group, PLLC**



Robert Furlani
Assistant General Counsel
& Chief Patent Counsel
Ligand Pharmaceuticals



Erica Norey
Senior Counsel IP
for Global Business
Development & M&A
Sanofi

Supporting Sponsor



Associate Sponsors



REGISTER NOW AmericanConference.com/IPDueDiligence • 888 224 2480

Part of C5 Group's
LIFE SCIENCES GLOBAL SERIES

NEW YEAR NEW QUARTER NEW LOCATION

Returning to New York City, **Life Sciences IP Due Diligence** brings together a premier faculty of in-house and law firm life sciences IP leaders to examine the latest market developments and provide actionable insights on:

- **Revamping your IP due diligence checklist** to align with evolving agency policy and regulatory priorities
- **Preparing** for the impending **patent super-cliff** and its impact on **portfolio value, exclusivity, and deal strategy**
- **Mitigating risk and strengthening transaction strategies** when assessing method-of-use (MOU) and obviousness-type double patenting (ODP) challenges
- **Unlocking hidden value** around **trade secrets** and evaluating their growing importance within life sciences IP portfolios
- Navigating the opportunities and complexities of **Chinese innovation** when evaluating global transactions and partnerships
- **Aligning your due diligence approach with emerging market trends** to identify opportunities, anticipate risks, and make more informed investment decisions



PLUS! Two industry roundtables designed to strengthen cross-functional collaboration, and apply IP due diligence best practices to real-world transactions:


Market and Regulation in Conversation

Connect market trends and regulatory developments to smarter diligence strategies and stronger deal outcomes.

Understanding the Business of IP Due Diligence

Enhance collaboration across legal, commercial, and IP teams to better identify risks, uncover opportunities, and maximize transaction value.





The market is changing, and you need to keep up.

Intellectual property sits at the heart of every major Life Sciences deal. However, global trade regulations and trends have shifted and the market is in flux. From value, to research and development, to ownership and exclusivity—accurate assessment of IP assets is critical.

Does your IP Due Diligence checklist still measure up?



Attend ACI's **9th Annual Summit on Life Sciences IP Due Diligence** to revamp your checklist and understand the dynamics dramatically altering the diligence review process.

We heard your feedback, and that's why we are coming back to the city where we started. We've also moved out of Q4 and into Q1, allowing you to start your fiscal year with a bang—this **February 9–10** at the **New York City Bar Association**.

Good IP is still good IP, but agency leadership changes, new threats to method-of-use patents, and heavily regulated global trade deals have made it so the cheese can no longer stand alone.

Keeping your IP due diligence checklist adaptable to the current market is the key to unlocking the highest value possible in life sciences deals.

We'll come together to unpack insights from **J.P. Morgan** on the **growth of mergers, acquisitions, and licensing deals in 2026 and 2027** all in the context of evolving **legislative activity** and **agency policy**.

We'll also cover the nuts and bolts of life sciences IP due diligence, tackling **obviousness-type double patenting, section 101 subject matter eligibility, skinny labeling**, and more.

Plus, we'll offer tips, tricks, and tools to practice with **speed** and **precision** as diligence gets more and more demanding, especially with the **patent super-cliff** looming on the horizon.

Our highly skilled faculty of life sciences thought leaders—comprised of premier in-house counsel and renowned law firm counsel—will break down how these shifts in the life sciences dealmaking landscape will be integrated into your diligence processes, giving you the space you need to evolve, adapt, and grow alongside your colleagues.

Benchmark, build, and bolster your diligence at this time-tested program—a must attend event for ensuring robust and high value due diligence reviews in an increasingly complex deal-making environment.

REGISTER TODAY

“
Hearing from
professionals
involved in due
diligence on a
daily basis was
very informative.”

2025 CONFERENCE ATTENDEE

SPEAKER FACULTY

Co-Chairs



Thomas L. Irving
Senior Partner
The Marbury Law Group, PLLC



Robert Furlani
Assistant General Counsel
& Chief Patent Counsel
Ligand Pharmaceuticals



Erica Norey
Senior Counsel IP
for Global Business
Development & M&A
Sanofi

Association Representative



John Nappi
Assistant General Counsel
**Pharmaceutical Research
& Manufacturers
of America**

In-House



Jennifer Friel Goldstein
Head of Relationship
Management
**First Citizens
Innovation Banking**



Donna Meuth
Associate General Counsel
Intellectual Property
Eisai



Christine Norris
Senior Corporate Counsel,
Intellectual Property
Charles River



Victoria Pedanou, PhD JD
Counsel, Global Biologics
Intellectual Property, Legal,
Ethics & Business Integrity
Sanofi



Michael Penn
Vice President,
Intellectual Property
BlueRock Therapeutics



Christine Rea Prihoda
Counsel, Strategic
Transactions and M&A
Gilead Sciences Inc



Rana Sawaya
Senior Director – Assistant
General Counsel – IP
**Regeneron
Pharmaceuticals Inc**



Keith Syverson
Director, IP Transactions
Novartis

Law Firm Counsel



Kathleen Gersh
Co-Chair, Life Sciences
Loeb & Loeb LLP



Michael B. Harlin
Partner
**Neal, Gerber &
Eisenberg LLP**



Mercedes Meyer
Partner
Banner Witcoff



Gregory A. Morris
Partner
Proskauer Rose LLP



Caitlin Olwell
Partner
**Akin Gump Strauss
Hauer & Feld LLP**



Svetlana Pavlovic
Counsel
**Akin Gump Strauss
Hauer & Feld LLP**



Alicia A. Russo
Partner
Venable LLP

DAY ONE

Tuesday, February 9, 2027

8:00 Breakfast and Registration

8:45 Opening Remarks from the Co-Chairs



Thomas L. Irving
Senior Partner
The Marbury Law Group, PLLC



Robert Furlani
Assistant General Counsel
& Chief Patent Counsel
Ligand Pharmaceuticals



Erica Norey
Senior Counsel IP for Global
Business Development & M&A
Sanofi

10:00 **Legislative Review: Understanding How Life Sciences Legislation and Agency Policy Are Reshaping Your IP Due Diligence Checklist**

Throughout 2026, personnel changes at key agencies and legislative activity at the federal level made waves through the life sciences industry. With midterm elections, senatorial retirement, and legislative proposals on the horizon, we anticipate much more to come.

From trade policy and IP rights to drug pricing reform—federal policy and regulatory developments continue to reshape every facet of life sciences deal making. This session examine the impact of these developments and their implications for conducting life sciences IP due diligence in 2027.



John Nappi
Assistant General Counsel
Pharmaceutical Research & Manufacturers of America

10:30 Morning Coffee Break

10:45 **Unpacking J.P. Morgan: Insights on Mergers, Acquisitions, and Licensing Deals in 2026 and 2027**

Life sciences IP due diligence is one piece in the puzzle that is life sciences dealmaking. Market dynamics, competitive pressures, strategic priorities, and emerging opportunities rule the day, and provide the critical context in which these diligence processes are conducted.

Following the 44th Annual J.P. Morgan Healthcare Conference, this session will examine the key trends, deal drivers, and market developments influencing life sciences transactions, and explore what they mean for effective IP due diligence in 2027, including:

- Analyzing the last year of deals, mergers, acquisitions, and licensing in the life sciences
- Assessing the growth of deals in 2026 as compared to last year's predictions
- Anticipating the outcomes of 2027 following J.P. Morgan's predictions
- Understanding how royalty monetization has entered the fold

» *ANI Pharmaceuticals v. CG Oncology*



Jennifer Friel Goldstein
Head of Relationship Management
First Citizens Innovation Banking

12:00 Lunch



REGISTER NOW

AmericanConference.com/IPDueDiligence • 888 224 2480

Part of C5 Group's
LIFE SCIENCES GLOBAL SERIES

1:00 Roundtable: Market and Regulation in Conversation

Dealmaking in the life sciences is driven by two primary forces: the market, and the regulatory schema in which the market is functioning.

This roundtable session will bring business leaders and lawyers together to discuss the harmonies, dissonances, and opportunities that occur when these two forces meet.



Christine Rea Prihoda
Counsel, Strategic Transactions and M&A
Gilead Sciences Inc

1:30 Get the Skinny: Diligence Strategies Around MOU Patents in the Wake of Hikma

In June 2026 the Supreme Court ruled in *Hikma v. Amarin* that generic drug makers using skinny labeling did not inherently infringe on method-of-use (MOU) patents without clear, affirmative action to "bring about the desired result" of patent infringement, thus adding another layer to the diligence review surrounding MOU patents. This session will discuss:

- Identifying whether skinny labels are sufficiently "active" to induce infringement
- Determining which skinny labels may or may not survive a motion to dismiss
- Comparing and contrasting 'explicit encouragement' with omission on a skinny label
 - » Evaluating susceptible patents



Donna Meuth
Associate General Counsel
Intellectual Property
Eisai

2:30 Afternoon Networking Break**2:45 Baurin, Baumeister, and How the ODP Tug-of-War Complicates Due Diligence on All Sides**

ODP remains unsettled—if not chaotic—at the PTAB and in the courts. In *Ex parte Baurin* and *Ex parte Baumeister* PTAB panels reached opposing determinations.

In an Appeals Review Panel (ARP), the USPTO reversed the PTAB determination in *Baurin* and squared both *Baurin* and *Baumeister* as unpatentable in view of ODP. Now, with both cases on appeal to the Federal Circuit, suitors and targets alike face considerable ODP uncertainty as they attempt IP due diligence reviews. For practitioners on both sides, risk and value hang in the balance.

This session will discuss:

- Analyzing the ODP harassment argument
 - » *Collect*
 - » *Allergan*
 - » *Arkose*
 - » *Jentoft*
 - » *Van Ornum*
 - » *Mates*
 - » *Corteva*
 - » *Blanchard*
 - » *Fallaux*
 - » *Hubbell*
- Assessing patents for potential ODP problems
- Identifying ODP red flags in a patent portfolio
- Understanding the implications of ODP for an IP due diligence review
- Advising clients of risk in the midst of uncertainty



Kathleen Gersh
Co-Chair, Life Sciences
Loeb & Loeb LLP



Victoria Pedanou, PhD JD
Counsel, Global Biologics Intellectual
Property, Legal, Ethics & Business Integrity
Sanofi

Global Sponsorship Opportunities

With conferences held across the United States, the American Conference Institute (ACI) delivers a diverse portfolio of events and roundtables designed to provide timely business intelligence to senior decision-makers navigating today's most pressing challenges.



For more information please contact:
Aaron Goldstein
Senior Business Development Manager
Email: A.Goldstein@AmericanConference.com

3:45

Navigating a Narrower Section 101 Landscape: What It Means for Innovation, Investment, and IP Due Diligence

Since 2010, a series of Supreme Court decisions have narrowed the framework around subject matter eligibility (SME), greatly impacting life science inventions.

Patent eligibility is at the crux of patent value and investment interest, and without a clear structure governing patent approval, applicants and assessors are at odds. With new legislation on the horizon, a reliable framework may be coming into focus.

- Understanding the USPTO's April 2026 memorandum encouraging patent applicants to submit separate declarations supporting "subject matter eligibility" (SMEDs) in response to §101 rejections
- Unpacking the Patent Eligibility Restoration Act (PERA) and what it means for SME going forward
- Assessing life sciences inventions for eligibility under the current framework
- Identifying potential disqualifying factors in patents yet to be approved, and the impact on exclusivity timelines




Michael Penn
Vice President, Intellectual Property
BlueRock Therapeutics



Michael B. Harlin
Partner
Neal, Gerber & Eisenberg LLP

4:45

End of Day One



**EARN CLE/
ETHICS
CREDITS**

Accreditation will be sought in those jurisdictions requested by the registrants which have continuing education requirements. This course is identified as nontransitional for the purposes of CLE accreditation.

ACI certifies this activity has been approved for CLE credit by the New York State Continuing Legal Education Board.

ACI certifies this activity has been approved for CLE credit by the State Bar of California.

ACI has a dedicated team which processes requests for state approval. Please note that event accreditation varies by state and ACI will make every effort to process your request.

For more information on ACI's CLE process, visit:
www.AmericanConference.com/Accreditation/CLE

Media Partners:



REGISTER NOW

AmericanConference.com/IPDueDiligence • 888 224 2480

Part of C5 Group's
LIFE SCIENCES GLOBAL SERIES

DAY TWO

Wednesday, February 10, 2027

8:00 Breakfast and Registration

8:45 Opening Remarks from the Co-Chairs



Thomas L. Irving
Senior Partner
The Marbury Law Group, PLLC



Robert Furlani
Assistant General Counsel
& Chief Patent Counsel
Ligand Pharmaceuticals



Erica Norey
Senior Counsel IP for Global
Business Development & M&A
Sanofi

9:00 **Reshaping the Pie Chart: Understanding the Expanding Role of Trade Secrets and Copyrights in Life Sciences IP Due Diligence Assessment**

While patents remain the cornerstone of strong life sciences IP portfolios, trade secrets have steadily grown in importance. Now, with AI algorithms joining the fray, copyrights have also taken a noteworthy place in the conversation.

- Expanding your due diligence checklist to consider and assess trade secrets as part of the IP portfolio
- Analyzing the security of key trade secrets in the life sciences industries
 - » Enforceable confidentiality
 - » Robust NDAs
 - » On- and off-boarding procedures
- Identifying copyright concerns with AI and other development algorithms
- Ensuring R&D pipelines are free of potential leaks

10:00 **Too Much to Due, Not Enough Time: Tips, Tricks, and Tools for Quick IP Due Diligence Turnaround**

We've all been there. Your deadline is fast approaching, and there's a mountain of IP to get through.

Don't panic!

In this session, experienced practitioners will walk you through the tips, tricks, and tools you need to complete a robust life sciences IP due diligence when you don't have time to dawdle.



Thomas L. Irving
Senior Partner
The Marbury Law Group, PLLC

10:45 Morning Coffee Break



For over 40 years, American Conference Institute has provided the opportunities that bring together business leaders, professionals and international experts from around the world to learn, meet, network and make the contacts that create the opportunities. Our conferences and related products connect the power of people with the power of information, a powerful combination for business growth and success.

Join Our Email List to Stay Connected

SIGN UP TO RECEIVE EXCLUSIVE
DISCOUNTS, OFFERS AND
PROGRAM UPDATES

AmericanConference.com/join-our-email-list/

11:00 Peering over the Edge: Understanding How the Looming Life Sciences Patent Super-Cliff will Shake Up Your IP Due Diligence Review

2030 is poised to bring on a patent super-cliff that could cost the industry upwards of \$500 billion, with some estimates surpassing even that high value loss.

As patents—for both small and large molecule—drugs are about to expire, and their exclusivity ends, industry practitioners are wondering what the future will look like for existing patent portfolios, portfolio growth, and M&A activity in the buildup.

- Assessing existing patent portfolios and target patents
- Preparing for the large scale loss of exclusivity
- Anticipating the impact of the patent super-cliff on M&A activity before 2030
- Strategizing around the patent super-cliff to limit damage to the bottom line
- Breaking down what this means for the future of small molecules as well as the growing biosimilars market
- Looking to Keytruda's 2028 expiration as a guiding post for future activity



Alicia A. Russo
Partner
Venable LLP

12:00 Lunch

1:00 Roundtable: Understanding the Business of IP Due Diligence



The context in which IP due diligence is undertaken can change your approach. Understanding how the diligence report will be utilized in a deal is fundamental to developing a successful strategy, checklist, and timeline.

This session brings business development leadership front and center to discuss the ins and outs of what's a go, what's a no go, and what can kill a deal in the making.



Robert Furlani
Assistant General Counsel
& Chief Patent Counsel
Ligand Pharmaceuticals



Moderator:
Gregory A. Morris
Partner
Proskauer Rose LLP

1:45 From East to West: Ensuring Integrity for your Due Diligence Review in Chinese Dealmaking

The life sciences industry has seen a sharp increase in dealmaking with Chinese companies in recent months. Shorter clinical trial timelines, less stringent regulatory hurdles, and significant research and development in China have led to high interest from American and European pharma companies. Though lucrative, these deals come with additional concerns that must be considered and assessed when undertaking the IP due diligence process that is central to the deal. This session will discuss:

- Understanding the clinical trial boom and why it has spurred so much activity in China
- Unpacking the latest changes to the BIOSECURE Act and how they impact your due diligence checklist
- Comparing the Chinese regulatory schema to that of the country under the laws of which your company was created or organized and identifying additional necessary steps for home country approval
- Anticipating potential Complete Response Letters (CRLs) from the FDA due to insufficient clinical trial diversity, facility manufacturing deficiencies, or other unmet FDA requirements
- Looking to European and other multi-national companies to benchmark and compare Chinese dealmaking strategies



Rana Sawaya
Senior Director – Assistant General Counsel
– IP
Regeneron Pharmaceuticals Inc



Keith Syverson
Director, IP Transactions
Novartis

2:45 Afternoon Networking Break

3:00 Money, Money, Money: Government Funding, Bankruptcy, and How to Ensure your IP Survives in a Hostile Funding Environment

Research, development, mergers, acquisitions, pipelines, etc.—all critical components of the business of the life sciences industry—boil down to funding.

As federal funding for scientific research has dramatically shrunk, companies have had to look to other sources to facilitate the future of the industry. However, funding can often come with conditions on IP, which can place a thorn in the paw of a good deal.

This session will explore the intersection of funding and intellectual property across the entire life sciences company lifecycle, from early-stage financing and technology development through transactions, restructuring, and even bankruptcy.

Attendees will gain practical insights into how funding-related obligations can impact IP ownership, value, commercialization rights, and due diligence assessments.

Topics of discussion include:

- Considering the threat of Bayh-Dole when accepting government funding
- Understanding and identifying the contractual caveats and conditions at play when your company, or your target company, has used alternative funding sources in product development
 - » Foundations
 - » Other company investment
 - » Venture capital
- Flagging instances of litigation funding, and analyzing the underlying agreements made
- Untangling happens to existing IP when a company goes belly-up



Svetlana Pavlovic
Counsel

Akin Gump Strauss Hauer & Feld LLP

4:00 Keeping Up with AI in your Life Sciences IP Due Diligence Review

It's everywhere—in under a year AI has become an unavoidable reality across every industry. With AI seeping into the bones of every player in a life sciences deal, it's imperative that diligence processes understand the ways that AI has impacted the industry.

This session will discuss:

- Identifying patents that are in danger of, or have been formed from, data scraping and the litigation threats that may come as a result
- Ensuring statements made using AI tools are accurate, especially when AI has been used in patent preparation or prosecution
- Developing tools to spot AI usage in patent preparation and prosecution
- Fact-checking your AI tools when relying on them for analysis, summaries, or research
- Keeping an eye out for hallucinations in AI responses
- Determining where and when it is safe to use AI tools in the various steps of life sciences IP due diligence




Christine Norris
Senior Corporate Counsel,
Intellectual Property
Charles River



Caitlin Olwell
Partner
Akin Gump Strauss Hauer & Feld LLP

5:00 End of Day 2 | Conference Concludes



Don't Miss What's Next

Explore our Full Life Sciences Portfolio



ACI's 2nd Forum on
PHARMA & BIOTECH PATENT LITIGATION
USA & CANADA

October 14–16, 2026
New York, NY



6th Annual Passport to Proficiency on the Essentials of
Hatch-Waxman and BPCIA

October 20–29, 2026
Virtual Series



2ND ANNUAL WEST COAST SUMMIT FOR
Women Leaders
IN LIFE SCIENCES LAW

November 10–11, 2026
San Francisco, CA



31st Annual Conference on
DRUG & MEDICAL DEVICE LITIGATION

December 2–3, 2026
New York, NY



8th Annual Summit on
CONTROLLED SUBSTANCES
REGULATION, LITIGATION, AND ENFORCEMENT

February 4–5, 2027
Washington, DC



HEALTHCARE & LIFE SCIENCES AI SUMMIT

February 23–24, 2027
New York, NY



EUROPEAN SUMMIT FOR
Women Leaders
IN LIFE SCIENCES LAW

March 9–10, 2027
Brussels

American Conference Institute's 45th
FDA BOOT CAMP



March 23–24, 2027
New York, NY



23rd Annual Conference on
PARAGRAPH IV DISPUTES



April 13–14, 2027
New York, NY

VENUE INFORMATION

New York City Bar
42 W 44th St, New York, NY 10036

HOTEL

Sofitel New York
45 W 44th St, New York, NY 10036
Reservations: +1 212-354-8844

ACCOMMODATIONS

American Conference Institute is pleased to offer our delegates a limited number of hotel rooms at a negotiated rate. To take advantage of these rates, please contact the hotel directly and quote **"ACI Life Sciences IP Due Diligence."**

Please note that the guest room block cut-off date is **January 9, 2027**. After that date OR when the room block fills, guestroom availability and rate can no longer be guaranteed.

BOOK NOW



Book with Confidence!

Register and pay to lock in your early rate and be eligible for a full refund until **January 26, 2027**.

If you are unable to attend for any reason, you will have the following options:

- A full credit note for you, or a colleague to attend another event.
- A full refund.

All cancellations and changes must be submitted to CustomerService@AmericanConference.com by **January 26, 2027**.

3 Ways to Register



ONLINE:
AmericanConference.com/IPDueDiligence



EMAIL:
CustomerService@AmericanConference.com



PHONE:
1-888-224-2480

PRICING	SAVE \$300	SAVE \$100	
	Register & Pay by November 13, 2026	Register & Pay by January 5, 2027	Register & Pay after January 5, 2027
Conference	\$2295	\$2495	\$2595

All program participants will receive an online link to access the conference materials as part of their registration fee.
Additional copies of the Conference Materials available for \$199 per copy.

To update your contact information and preferences, please visit <https://www.AmericanConference.com/preference-center/>.
Terms & conditions and refund/cancellation policies can be found at [AmericanConference.com/company/faq/](https://www.AmericanConference.com/company/faq/)

REGISTRATION CODE:
B00-657-657L27.WEB

CONFERENCE CODE:
657L27-NYC

Bringing a Team?*

1-3	No Discount
4-8	10% Conference Discount
9-12	15% Conference Discount
12+	Call 888-224-2480

Special Discount

ACI offers financial scholarships for government employees, judges, law students, non-profit entities and others. For more information, please email or call customer service.

*Team/group registrations must be from the same organization/firm and register together in one transaction.